In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Infinity/Purdue: The Challenge of Reprising Roche/Genentech

Executive Summary

Infinity's "Big Brother" deal with the privately held affiliates Purdue and Mundipharma comes closest of any recent deal to replicating the structure of the Genentech/Roche relationship -- swapping the majority of a biotech's pipeline to a well-heeled partner in return for independence from the capital markets and enough commercial upside to deliver a long-term return for investors. But the idiosyncrasies of the Purdue/Mundipharma ownership and structure, and the recent stormy history that opened minds to the possibility of such a deal, show why further iterations of the model will remain a rarity.
Advertisement

Related Content

Biogen Idec Charts A New Course
Ironwood Pharmaceuticals: Independent for the Long Haul
Overcoming Disaster: What Biotechs Do When A Lead Asset Fails
Chiesi/Cornerstone: Trading Ownership for Pipeline
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2008
Biopharma in 2008: What a Difference an Economic Crisis Makes
Private Equity Comes to Discovery
The $100 Million IND
The $100 Million IND
Tramadol Reformulations Highlight Pain Challenges and Opportunities

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel